Alnylam Pharmaceuticals Reports 67% Revenue Growth to $1.29 Billion in Latest Quarter

Alnylam Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly filing, with total revenues reaching $1.29 billion for the three months ended June 30, 2026, a 67% increase from $773.7 million in the same period last year. The company achieved net product revenues of $1.17 billion, a 74% increase year-over-year, primarily driven by strong sales of its flagship product, AMVUTTRA, which saw a 124% increase in U.S. sales. The company also reported a net income of $164.5 million for the quarter, a substantial turnaround from a net loss of $72.2 million in the prior year.

Compared to the previous fiscal period, Alnylam's financial performance showed marked improvement, with total revenues for the six months ending June 30, 2026, increasing by 80% to $2.46 billion, up from $1.37 billion in the same period of 2025. The company’s operating costs also rose, totaling $1.06 billion for the quarter, up 34% from the previous year, largely due to increased costs associated with the production and commercialization of its products. Despite these rising costs, the company reported a significant operating income of $231.4 million, compared to an operating loss of $16.2 million in the same quarter last year.

Strategically, Alnylam has made notable advancements, including the launch of its "Alnylam 2030" strategy aimed at expanding its product pipeline and market presence. The company has six marketed products, including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, and is actively pursuing additional regulatory approvals and product launches. In July 2023, Alnylam entered into a collaboration agreement with Roche for the joint development of zilebesiran, further enhancing its research and development capabilities.

Operationally, Alnylam reported a total employee headcount of 1,200 as of June 30, 2026, reflecting its growth and expansion efforts. The company continues to invest heavily in research and development, with R&D expenses totaling $413.1 million for the quarter, a 28% increase from the previous year. This investment is aimed at advancing its clinical pipeline, which includes multiple late-stage programs and new therapeutic areas. Alnylam anticipates that its ongoing product launches and collaborations will continue to drive revenue growth, with expectations of maintaining profitability and expanding its market share in the coming years.

Looking ahead, Alnylam remains optimistic about its future, projecting continued revenue growth driven by its existing product portfolio and new product launches. The company expects to leverage its strong cash position, with cash and cash equivalents totaling $1.71 billion as of June 30, 2026, to support its operational and strategic initiatives. Alnylam's management emphasized the importance of executing its Alnylam 2030 strategy to achieve long-term growth and patient impact, while navigating the competitive landscape of the biopharmaceutical industry.